Hem › T-cellslymfom › Wisconsin
Kliniska studier för T-cellslymfom i Wisconsin
5 studier för T-cellslymfom söker deltagare vid platser i Wisconsin.
Städer i Wisconsin
Officiell studietext (engelska)
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
- Marshfield Medical Center-EC Cancer Center, Eau Claire
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
- och 5 fler
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 2 okt. 2026 · NCT04803201Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital of Wisconsin, Milwaukee
RekryterarObservationsstudie
Ålder 0 till 38 · Alla kön · Uppdaterad 1 okt. 2026 · NCT06131801Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- University of Wisconsin Carbone Cancer Center, Madison
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 25 sep. 2026 · NCT06561048Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
- Marshfield Medical Center-Marshfield, Marshfield
- och 9 fler
RekryterarFas 3
Ålder 18 till 75 · Alla kön · Uppdaterad 14 sep. 2026 · NCT06724237Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Children's Hospital of Wisconsin, Milwaukee
RekryterarFas 1
Ålder 1 till 21 · Alla kön · Uppdaterad 6 dec. 2024 · NCT05476770Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.